Table 3.

Interaction between ANO2 positivity and EBNA-1 IgG levels

Group of individuals	EBNA-1 IgG below median among controls				EBNA-1 IgG above median among controls				AP (95% CI)	P valueAP
	No. of cases	No. of controls	OR (95% CI)	P value	No. of cases	No. of controls	OR (95% CI)	P value
All cases and controls
ANO2−	312	531	1.0 (–)	—	586	540	1.9 (1.6–2.3)	4 × 10−11	0.7 (0.5–0.9)	2 × 10−9
ANO2+	50	22	4.0 (2.4–6.8)	3 × 10−7	115	13	15.7 (8.6–28.4)	2 × 10−16
Individuals who are HLA-DRB1*15−
ANO2−	188	419	1.0 (–)	—	280	381	1.7 (1.4–2.2)	2 × 10−5	0.7 (0.5–0.9)	5 × 10−8
ANO2+	24	17	3.4 (1.7–6.5)	4 × 10−4	50	9	13.9 (6.8–29.5)	2 × 10−12
Individuals who are HLA-DRB1*15+
ANO2−	132	112	1.0 (–)	—	306	159	1.7 (1.2–2.4)	2 × 10−3	0.6 (0.1–1.1)	2 × 10−2
ANO2+	26	5	4.6 (1.7–12.4)	3 × 10−3	65	4	14.0 (4.9–40.1)	9 × 10−7

Adjusted ORs with 95% CIs of developing MS for ANO2 positivity and different combinations HLA-DRB1*15 status and EBNA-1 IgG levels.